ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ACHV Achieve Life Sciences Inc

4.70
0.125 (2.73%)
27 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Achieve Life Sciences Inc NASDAQ:ACHV NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.125 2.73% 4.70 2.65 6.90 4.64 4.48 4.57 57,002 05:00:00

Achieve Life Sciences to Present at Oppenheimer's 29th Annual Healthcare Conference on March 20, 2019

18/03/2019 9:30am

PR Newswire (US)


Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Achieve Life Sciences Charts.

SEATTLE and VANCOUVER, British Columbia, March 18, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that Rick Stewart, Chairman and Chief Executive Officer, will present at Oppenheimer's 29th Annual Healthcare Conference in New York on Wednesday, March 20 at 2:10 p.m. Eastern Time.

Achieve logo (PRNewsfoto/Achieve Life Sciences, Inc.)

A live webcast of the presentation can be accessed at http://ir.achievelifesciences.com/events-and-webcasts. A replay of the webcast will also be archived on Achieve's website following the conference. 

About Achieve
Tobacco use is currently the leading cause of preventable death and is responsible for nearly seven million deaths annually worldwide1. It is estimated that 28.7% of cancer deaths in the U.S. are attributable to cigarette smoking2.

Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.

As an approved, branded product in Central and Eastern Europe for more than two decades, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction.

Achieve Contact
Jason Wong
jwong@bplifescience.com 
(415) 375-3340 ext. 4

1 World Health Organization. WHO Report on the Global Tobacco Epidemic, 2017. Geneva: World Health Organization, 2017
2 Annals of Epidemiology, Volume 25, Issue 3, 179 - 182.e1

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/achieve-life-sciences-to-present-at-oppenheimers-29th-annual-healthcare-conference-on-march-20-2019-300813491.html

SOURCE Achieve Life Sciences, Inc.

Copyright 2019 PR Newswire

1 Year Achieve Life Sciences Chart

1 Year Achieve Life Sciences Chart

1 Month Achieve Life Sciences Chart

1 Month Achieve Life Sciences Chart

Your Recent History

Delayed Upgrade Clock